ROIVANT SCIENCES LTD. Payments to Acquire Marketable Securities
ROIVANT SCIENCES LTD. (ROIV) reported Payments to Acquire Marketable Securities of $3.79 billion for the 9-month period ending 2025-12-31, per its 10-Q filed 2026-02-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-02-06
- ROIVANT SCIENCES LTD. payments to acquire marketable securities for the quarter ending 2025-12-31 was $1.01B, a 53.93% increase year-over-year.
- ROIVANT SCIENCES LTD. payments to acquire marketable securities for the quarter ending 2025-09-30 was $976.73M, a 71.30% decline year-over-year.
- ROIVANT SCIENCES LTD. payments to acquire marketable securities for the quarter ending 2025-06-30 was $1.80B.
- ROIVANT SCIENCES LTD. payments to acquire marketable securities for the quarter ending 2025-03-31 was $0.00.
- ROIVANT SCIENCES LTD. payments to acquire marketable securities for fiscal 2025 was $4.06B.
- ROIVANT SCIENCES LTD. payments to acquire marketable securities for fiscal 2024 was $0.00.
- ROIVANT SCIENCES LTD. payments to acquire marketable securities for fiscal 2023 was $0.00.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.01B derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | $1.99B derived: sum of 2 quarters · filed 2026-02-06 | $3.79B 10-Q · filed 2026-02-06 | $3.79B derived: sum of 4 quarters · filed 2026-02-06 |
| 2025-09-30 | $976.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | $2.78B 10-Q · filed 2025-11-10 | $2.78B derived: sum of 3 quarters · filed 2025-11-10 | $3.44B derived: sum of 4 quarters · filed 2026-02-06 |
| 2025-06-30 | $1.80B 10-Q · filed 2025-08-11 | $1.80B derived: sum of 2 quarters · filed 2025-08-11 | $2.46B derived: sum of 3 quarters · filed 2026-02-06 | $5.86B derived: sum of 4 quarters · filed 2026-02-06 |
| 2025-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | $658.54M derived: sum of 2 quarters · filed 2026-02-06 | $4.06B derived: sum of 3 quarters · filed 2026-02-06 | $4.06B 10-K · filed 2025-05-29 |
| 2024-12-31 | $658.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | $4.06B derived: sum of 2 quarters · filed 2026-02-06 | $4.06B 10-Q · filed 2026-02-06 | $4.06B derived: sum of 4 quarters · filed 2026-02-06 |
| 2024-09-30 | $3.40B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | $3.40B 10-Q · filed 2025-11-10 | $3.40B derived: sum of 3 quarters · filed 2025-11-10 | $3.40B derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-11 | $0.00 derived: sum of 2 quarters · filed 2025-08-11 | $0.00 derived: sum of 3 quarters · filed 2025-08-11 | |
| 2024-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | $0.00 derived: sum of 2 quarters · filed 2025-05-29 | $0.00 10-K · filed 2025-05-29 | |
| 2023-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-10 | $0.00 10-Q · filed 2025-02-10 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | |||
| 2023-03-31 | $0.00 10-K · filed 2025-05-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |